<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Prognostic Value of Metabolic Tumor Burden from18 F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer" /><meta property="og:locale" content="en" /><meta name="description" content="Objective" /><meta property="og:description" content="Objective" /><link rel="canonical" href="https://clinicaltree.github.io/posts/prognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/prognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2012-12-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Prognostic Value of Metabolic Tumor Burden from18 F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2012-12-31T17:00:00+00:00","description":"Objective","headline":"Prognostic Value of Metabolic Tumor Burden from18 F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/prognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell/"},"url":"https://clinicaltree.github.io/posts/prognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell/"}</script><title>Prognostic Value of Metabolic Tumor Burden from18 F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Prognostic Value of Metabolic Tumor Burden from18 F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Prognostic Value of Metabolic Tumor Burden from18 F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1356973200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Dec 31, 2012 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Hao Zhang MD PhD</a> </em>, <em> <a href="">Kristen Wroblewski MS</a> </em>, <em> <a href="">Shengri Liao MD PhD</a> </em>, <em> <a href="">Rony Kampalath MD</a> </em>, <em> <a href="">Bill C. Penney PhD</a> </em>, <em> <a href="">Yi Zhang MD</a> </em>, <em> <a href="">Yonglin Pu MD PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2732 words"> <em>15 min</em> read</span></div></div></div><div class="post-content"><h2 id="objective"><span class="mr-2">Objective</span><a href="#objective" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To assess the prognostic value of metabolic tumor burden as measured with metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on 2-deoxy-2-( 18 F)fluoro-D-glucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT), independent of current Union Internacional Contra la Cancrum/American Joint Committee on Cancer tumor, node, and metastasis (TNM) stage; in comparison with that of standardized uptake value (SUV) in surgical patients with non–small-cell lung cancer (NSCLC).</p><h2 id="material-and-methods"><span class="mr-2">Material and Methods</span><a href="#material-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>This study retrospectively reviewed 104 consecutive surgical patients (47 males, 57 females, median age at PET/CT scan of 67.92 years) with diagnosed stage I to IV NSCLC who had baseline 18 F-FDG PET/CT scans. The 18 F-FDG PET/CT scans were performed in accordance with National Cancer Institute guidelines. The MTV of tumors in the whole body (MTV WB ), TLG of tumors in the whole body (TLG WB ), the maximum standardized uptake value of tumors in the whole body (SUV maxWB ) as well as the mean standardized uptake value of tumor in the whole body (SUV meanWB ) were measured. The median follow-up among 67 survivors was 42.07 months from the PET/CT (range 2.82–80.95 months). Statistical methods included Kaplan-Meier curves, Cox regression, and C-statistics. The interobserver variability of SUV maxWB , SUV meanWB , MTV WB , and TLG WB between two observers was analyzed using concordance correlation coefficients (CCCs).</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The interobserver variability of SUV maxWB , SUV meanWB , MTV WB and TLG WB was very low with CCCs greater than 0.882. There was a statistically significant association of stage with overall survival (OS). The hazard ratio (HR) of stage III and stage IV as compared with stage I was 3.60 ( <em>P</em> = .001) and 4.00 ( <em>P</em> = .013), respectively. The MTV WB was significantly associated with OS with a HR for 1-unit increase of ln(MTV WB ) of 1.40/1.32 ( <em>P</em> = .004/.039), before/after adjusting for stage and other prognostic factors including chemoradiation therapy, and surgical procedure, respectively. TLG WB had a statistically significant association with OS before and after adjusting for stage and the other prognostic factors. The HR for 1-unit increase in ln(TLG WB ) was 1.26 ( <em>P</em> = .011) and 1.25 ( <em>P</em> = .031), before and after the adjustment, respectively. Subjects with conditions that led to pneumonectomy (HR = 2.82, <em>P</em> = .035) or segmental resection (HR = 3.44, <em>P</em> = .044) had significantly worse survival than those needing lobectomy. There was no statistically significant association between OS and age, gender, tumor histology, ln(SUV maxWB ), and ln(SUV meanWB ) (all <em>P</em> &gt; .05). There were 37 deaths during follow-up.</p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Baseline whole-body metabolic tumor burden as measured with MTV WB and TLG WB on FDG PET is a prognostic measure independent of clinical stage and other prognostic factors including chemoradiation therapy and surgical procedure with low interobserver variability and may be used to further risk stratify surgical patients with NSCLC. This study also suggests that MTV and TLG are better prognostic measures than SUV max and SUV mean . These results will need to be validated in larger cohorts in a prospective study.</p><p>Lung cancer is the most common cause of cancer death in the world , the second most common cancer in both men and women, and the number one cause of cancer-related deaths in the United States. Non–small-cell lung cancer (NSCLC) comprises 80%–85% of all lung cancer cases . The treatment and prognosis of NSCLC depend mainly on disease stage as defined by the Union Internacional Contra la Cancrum (UICC)/American Joint Committee on Cancer (AJCC) . The stage based on the evaluation of the T, N, and M components and the assignment to a stage grouping (I to IV) is the single most prognostic factor in predicting the outcomes of both surgical and nonsurgical patients with NSCLC . A retrospective study from the Netherlands that examined outcomes of 2361 patients who underwent surgery for resectable NSCLC from 1970 to 1992 found that the 5-year survival rate ranges from 19% in stage IIIA to 63% in stage IA . In a multicenter North American clinical trial , involving 458 patients with unresectable NSCLC cancers, but without metastases or significant weight loss, the patients were randomized to three groups: standard once-daily radiation therapy alone; chemotherapy, followed by standard radiation; and hyperfractionated radiation. Five-year survival rates were only 5%, 8%, and 6% in these three groups, respectively. These two studies highlight the dramatic difference in survival between surgical and nonsurgical patients with NSCLC.</p><p>Recently several studies demonstrated that metabolic tumor burden as measured with metabolic tumor volume (MTV) or total lesion glycolysis (TLG) is a prognostic marker in nonsurgical patients with NSCLC independent of TNM tumor stage . However, none of the studies specifically studied its prognostic value in the surgical patients. Lee et al was the first who found that the baseline whole body MTV (MTV WB ) measured semiautomatically is a statistically significant prognostic index and better than SUV max and SUV mean in the prediction of patient outcome in 19 lung cancer patients treated with different modalities . In their recent study, they expanded to a cohort of 61 patients with NSCLC treated with different modalities and confirmed the significant association of high MTV WB with decreased overall and progression-free survival in patients who received definitive therapy . In another recent study in 120 patients treated nonsurgically with advanced NSCLC by Yan et al, MTV of the primary tumor was found to be an important independent prognostic factor of survival and better than the SUV max in this regard. More recent studies showed that baseline whole-body metabolic tumor burden as measured with MTV and TLG on positron emission tomography (PET) is a prognostic measure independent of clinical stage in nonsurgical patients and in homogeneous stage IV NSCLC . However, based on our extensive literature search, there was no report in the literature about the prognostic value of the MTV and TLG in surgical patients with NSCLC independent of the clinical TNM stage.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-recruitment"><span class="mr-2">Patient Recruitment</span><a href="#patient-recruitment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="imaging-protocols"><span class="mr-2">Imaging Protocols</span><a href="#imaging-protocols" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="petct-imaging"><span class="mr-2">PET/CT imaging</span><a href="#petct-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="measurement-of-tumor-volume-on-petct"><span class="mr-2">Measurement of tumor volume on PET/CT</span><a href="#measurement-of-tumor-volume-on-petct" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueofMetabolicTumorBurdenfrom18FFDGPETinSurgicalPatientswithNonsmallcellLungCancer/0_1s20S1076633212003790.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueofMetabolicTumorBurdenfrom18FFDGPETinSurgicalPatientswithNonsmallcellLungCancer/0_1s20S1076633212003790.jpg" alt="Figure 1, Axial, sagittal, and coronal images from a positron emission tomography scan of a 67-year-old female with a new diagnosis of non–small-cell lung cancer, showing the tumor contours for the measurement of the maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, and total lesion glycolysis of tumors with the MIMvista PETedge tool." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Patient Characteristics and Overall Survival Based on Stage, Gender, Age, Tumor Histology, Treatment, and PET/CT Measurements in 104 Surgical Patients with Non–small-cell Lung Cancer</p><p>Mean (SD) Survival Rate 1 year (%) 3 years (%) 5 years (%) Overall <em>n</em> = 104 92.13 74.10 58.32 Stage I, <em>n</em> = 66 96.87 82.08 66.92 II, <em>n</em> = 18 88.89 82.54 74.29 III, <em>n</em> = 14 78.57 39.29 20.95 IV, <em>n</em> = 6 83.33 41.67 20.83 Gender Female, <em>n</em> = 57 92.85 79.37 68.88 Male, <em>n</em> = 47 91.20 67.71 48.00 Age at PET scan (y) 67.36 (10.08) ≤67.92 (median), <em>n</em> = 52 88.30 80.13 67.37 &gt;67.92, <em>n</em> = 52 96.08 67.76 47.39 Histology Adeno, <em>n</em> = 52 90.15 77.70 58.05 Squamous, <em>n</em> = 32 100.00 76.52 57.77 Large, <em>n</em> = 8 100.00 83.33 83.33 Others, <em>n</em> = 12 74.07 42.33 42.33 Chemoradiation None, <em>n</em> = 59 93.06 76.61 59.27 Chemo, <em>n</em> = 31 93.21 82.13 76.66 RT, <em>n</em> = 3 66.67 33.33 N/A Chemo+RT, <em>n</em> = 11 90.91 45.45 17.05 Surgery Lobectomy, <em>n</em> = 82 95.08 78.05 62.85 Pneum, <em>n</em> = 9 75.00 45.00 22.50 Segmental, <em>n</em> = 4 75.00 25.00 25.00 Wedge, <em>n</em> = 9 87.50 87.50 65.63<em>SUV__maxWB</em> 7.57 (5.79) ≤11.59, <em>n</em> = 80 96.07 79.55 63.34 &gt;11.59, <em>n</em> = 24 79.17 55.88 41.91<em>SUV__meanWB</em> 3.30 (1.85) ≤2.14, <em>n</em> = 33 100.00 87.14 70.76 &gt;2.14, <em>n</em> = 71 88.42 67.71 52.06<em>MTV__WB</em> 49.72 (143.33) ≤37.34, <em>n</em> = 78 96.05 82.14 67.26 &gt;37.34, <em>n</em> = 26 80.42 48.74 31.59<em>TLG__WB</em> 208.96 (493.90) ≤407.48, <em>n</em> = 90 96.57 79.58 64.74 &gt;407.48, <em>n</em> = 14 62.86 35.92 11.97</p><p>Adeno, adenocarcinoma; chemo, chemotherapy; chemo+RT, chemoradiation therapy; histology, tumor histology; large, large cell carcinoma; MTV, metabolic tumor volume; MTV WB , MTV of tumors in the whole body; none, no chemoradiation; pneum, pneumonectomy; RT, radiation therapy; SD, standard deviation; segmental, segmental resection; squamous, squamous cell carcinoma; others, other tumor histology; SUV max , maximum standardized uptake value; SUV maxWB , SUV max of tumors in the whole body; SUV mean , mean standardized uptake value; SUV meanWB , SUV mean of tumors in the whole body; TLG, total lesion glycolysis; TLG WB , TLG of tumors in the whole body; wedge, wedge resection; ≤, equal or less than a cutoff point (defined based on receiver operating characteristic curve analysis unless otherwise noted); &gt;, greater than the cutoff point.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueofMetabolicTumorBurdenfrom18FFDGPETinSurgicalPatientswithNonsmallcellLungCancer/1_1s20S1076633212003790.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueofMetabolicTumorBurdenfrom18FFDGPETinSurgicalPatientswithNonsmallcellLungCancer/1_1s20S1076633212003790.jpg" alt="Figure 2, Kaplan-Meier curves of overall survival after baseline positron emission tomography/computed tomography based on clinical stage in 104 surgical patients with stage I to IV non–small-cell lung cancer." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueofMetabolicTumorBurdenfrom18FFDGPETinSurgicalPatientswithNonsmallcellLungCancer/2_1s20S1076633212003790.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueofMetabolicTumorBurdenfrom18FFDGPETinSurgicalPatientswithNonsmallcellLungCancer/2_1s20S1076633212003790.jpg" alt="Figure 3, Kaplan-Meier curves of overall survival after baseline positron emission tomography (PET)/CT grouped according to PET measurements in 104 surgical patients with stage I to IV non–small-cell lung cancer. (a) Whole-body tumor maximum standardized uptake value (SUV max ), (b) whole-body tumor mean standardized uptake value (SUV mean ), (c) whole-body metabolic tumor volume (MTV), (d) whole-body total lesion glycolysis (TLG)." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>Association of Overall Survival (OS) with Stage, Gender, Age, Tumor Histology, Treatment, and PET/CT Measurements in 104 Surgical Patients with Non–small-cell Lung Cancer</p><p>Univariate Analysis Multivariate Analysis HR (95% CI)<em>P</em> Value HR ∗ (95% CI)<em>P</em> Value ∗ C-statistic Stage C-statistic = 0.59<em>I</em> Reference_II_ 1.04 (0.38–2.79) .946 III 3.60 (1.66–7.83) .001 IV 4.00 (1.34–11.90) .013 Gender Female Reference Male 1.62 (0.85–3.11) .146 Age 1.03 (0.99–1.06) .163 Histology Adeno Reference Squamous 0.89 (0.42–1.88) .752 Large 0.31 (0.04–2.33) .256 Others 2.06 (0.85–4.99) .109 Chemoradiation None Reference Chemo 0.55 (0.23–1.31) .177 RT 4.93 (1.45–16.80) .011 Chemo+RT 2.65 (1.11–6.30) .027 Surgery Lobectomy Reference Pneum 2.82 (1.08–7.39) .035 Segmental 3.44 (1.03–11.48) .044 Wedge 1.12 (0.34–3.72) .856 SUV max C-statistic = 0.58<em>ln(SUV__maxWB__)</em> 1.36 (0.93–1.99) .111 1.45 (0.91–2.30) 0.120 0.69 SUV mean C-statistic=0.57<em>ln(SUV__meanWB__)</em> 1.43 (0.87–2.35) .160 1.73 (0.91–3.29) 0.094 0.70 MTV C-statistic = 0.63<em>ln(MTV__WB__)</em> 1.40 (1.11–1.76) .004 1.32 (1.01–1.72) 0.039 0.69 TLG C-statistic = 0.63<em>ln(TLG__WB__)</em> 1.26 (1.05–1.50) .011 1.25 (1.02–1.54) 0.031 0.70</p><p>CI, confidence interval; HR, hazard ratio; C-statistic, Gönen and Heller’s K concordance measure; ln, natural log; other abbreviations are as in Table 1 .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 3</p><p>Association of Overall Survival (OS) with Stage, Gender, Age, and PET/CT Measurements in 59 Surgical Patients with Non–small cell Lung Cancer Treated with Surgery Only</p><p>Univariate Analysis Multivariate Analysis HR (95% CI)<em>P</em> Value HR ∗ (95% CI)<em>P</em> Value ∗ C-statistic Stage C-statistic= 0.57<em>I+II, n</em> = 52 Reference_III+_ IV, <em>n</em> =7 5.50 (2.04–14.82) .001 Gender Female, <em>n</em> = 35 Reference Male, <em>n</em> = 24 1.67 (0.69–4.04) .253 Age 1.01 (0.96–1.06) .657 SUV max <em>ln(SUV__maxWB__)</em> 1.63 (0.98–2.71) .061 1.54 (0.90–2.64) .115 0.66 SUV mean <em>ln(SUV__meanWB__)</em> 1.92 (0.96–3.85) .064 1.95 (0.91–4.17) .085 0.67 MTV_ln(MTV__WB__)_ 1.65 (1.20–2.28) .002 1.47 (1.04–2.08) .031 0.67 TLG_ln(TLG__WB__)_ 1.43 (1.12–1.84) .005 1.34 (1.03–1.73) .030 0.68</p><p>CI, confidence interval; HR, hazard ratio; C-statistic, Gönen and Heller’s K concordance measure; ln, natural log; other abbreviations are as in Table 1 .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusion-1"><span class="mr-2">Conclusion</span><a href="#conclusion-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgments"><span class="mr-2">Acknowledgments</span><a href="#acknowledgments" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Parkin D.M., Bray F.I., Devesa S.S.: Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37: pp. S4-66.</p><li><p>2. Traynor A.M., Schiller J.H.: Systemic treatment of advanced non-small cell lung cancer. Drugs of Today 2004; 40: pp. 697-710.</p><li><p>3. UyBico S.J., Wu C.C., Suh R.D., et. al.: Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 2010; 30: pp. 1163-1181.</p><li><p>4. American Joint Committee on Cancer: AJCC Cancer Staging Manual.6th ed.2002.SpringerNew York, NY</p><li><p>5. Lung.Edge S.B.Byrd D.R.Compton C.C. et. al.AJCC Cancer Staging Manual.2010.SpringerNew York, NY:pp. 253-270.</p><li><p>6. Mountain C.F.: Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: pp. 1710-1717.</p><li><p>7. Adebonojo S.A., Bowser A.N., Moritz D.M., et. al.: Impact of revised stage classification of lung cancer on survival: a military experience. Chest 1999; 115: pp. 1507-1513.</p><li><p>8. van Rens M.T., de la Riviere A.B., Elbers H.R., et. al.: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non–small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117: pp. 374-379.</p><li><p>9. Sause W., Kolesar P., Taylor I.V.S., et. al.: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: pp. 358-364.</p><li><p>10. Liao S., Penney B.C., Wroblewski K., et. al.: Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012; 39: pp. 27-38.</p><li><p>11. Liao S., Penney B.C., Zhang H., et. al.: Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV non-surgical small cell lung cancer. Acad Radiol 2012; 19: pp. 69-77.</p><li><p>12. Yan H., Wang R., Zhao F., et. al.: Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Acta Radiol 2011; 52: pp. 646-650.</p><li><p>13. Lee P., Weerasuriya D.K., Lavori P.W., et. al.: Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007; 69: pp. 328-333.</p><li><p>14. Lee P., Bazan J.G., Lavori P.W., et. al.: Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer 2012; 13: pp. 52-58.</p><li><p>15. Shankar L.K., Hoffman J.M., Bacharach S., et. al.: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: pp. 1059-1066.</p><li><p>16. Werner-Wasik M., Nelson A.D., Choi W., et. al.: What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 2012; 82: pp. 1164-1171.</p><li><p>17. Lin L.I.: A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: pp. 255-268.</p><li><p>18. Lin L.I.: A note on the concordance correlation coefficient. Biometrics 2000; 56: pp. 324-325.</p><li><p>19. Cox D.R.: Regression models and life-tables (with discussion). J Royal Stat Soc Series B 1972; 34: pp. 187-220.</p><li><p>20. Gönen M., Heller G.: Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005; 92: pp. 965-970.</p><li><p>21. Grambsch P.M., Therneau T.M.: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: pp. 515-526.</p><li><p>22. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: pp. 457-481.</p><li><p>23. van Baardwijk A., Dooms C., van Suylen R.J., et. al.: The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007; 43: pp. 1392-1398.</p><li><p>24. Downey R.J., Akhurst T., Gonen M., et. al.: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: pp. 3255-3260.</p><li><p>25. Agarwal M., Brahmanday G., Bajaj S.K., et. al.: Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I &amp; II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 2010; 37: pp. 691-698.</p><li><p>26. Vesselle H., Freeman J.D., Wiens L., et. al.: Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007; 13: pp. 3255-3263.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-20/'>Volume 20</a>, <a href='/categories/issue-1/'>Issue 1</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Prognostic%20Value%20of%20Metabolic%20Tumor%20Burden%20from18%20F-FDG%20PET%20in%20Surgical%20Patients%20with%20Non%E2%80%93small-cell%20Lung%20Cancer%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fprognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Prognostic%20Value%20of%20Metabolic%20Tumor%20Burden%20from18%20F-FDG%20PET%20in%20Surgical%20Patients%20with%20Non%E2%80%93small-cell%20Lung%20Cancer%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fprognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fprognostic-value-of-metabolic-tumor-burden-from18-f-fdg-pet-in-surgical-patients-with-non-small-cell%2F&text=Prognostic%20Value%20of%20Metabolic%20Tumor%20Burden%20from18%20F-FDG%20PET%20in%20Surgical%20Patients%20with%20Non%E2%80%93small-cell%20Lung%20Cancer%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/after-hours-coverage-of-various-radiologic-subspecialties-and-its-impact-on-the-fourth-year-radiolog/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>After-hours Coverage of Various Radiologic Subspecialties and Its Impact on the Fourth-year Radiology Residency Curriculum</h3><div class="text-muted small"><p> Rationale and Objective The modification of the initial radiology board exam series has as a concerted aim the promotion of subspecialization. Yet, in practice, fellowship-trained radiologists may...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-semi-automatic-volumetric-vx2-hepatic-tumor-segmentation-from-cone-beam-ct-and-multi-d/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of Semi-automatic Volumetric VX2 Hepatic Tumor Segmentation from Cone Beam CT and Multi-detector CT with Histology in Rabbit Models</h3><div class="text-muted small"><p> Rationale and Objectives The purpose of this study was to compare tumor volume in a VX2 rabbit model as calculated using semiautomatic tumor segmentation from C-arm cone-beam computed tomography (...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-t1-dgemric-and-quantitative-t2-mri-in-preoperative-acl-rupture-patients/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of T1ρ, dGEMRIC, and Quantitative T2 MRI in Preoperative ACL Rupture Patients</h3><div class="text-muted small"><p> Rationale and Objectives T1ρ, inversion recovery sequence with a gadolinium contrast agent (dGEMRIC), and T2 mapping have shown sensitivity toward different osteoarthritic-associated compositional...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/preoperative-ct-findings-of-thymoma-are-correlated-with-postoperative-masaoka-clinical-stage/" class="btn btn-outline-primary" prompt="Older"><p>Preoperative CT Findings of Thymoma are Correlated with Postoperative Masaoka Clinical Stage</p></a> <a href="/posts/quantification-of-intracranial-aneurysm-morphodynamics-from-ecg-gated-ct-angiography/" class="btn btn-outline-primary" prompt="Newer"><p>Quantification of Intracranial Aneurysm Morphodynamics from ECG-gated CT Angiography</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
